Evidence map›Paper›PMID 38055177›Full record

ArticleCardiology and therapy2024

Impact of Access Site on Periprocedural Bleeding and Cerebral and Coronary Events in High-Bleeding-Risk Percutaneous Coronary Intervention: Findings from the RIVA-PCI Trial.

Martin Borlich, Uwe Zeymer, Harm Wienbergen, Hans-Peter Hobbach, Alessandro Cuneo, Raffi Bekeredjian, Oliver Ritter, Birgit Hailer, Klaus Hertting, Marcus Hennersdorf and 13 more

Open access · goldAbstract read
In one paragraph

Article in Cardiology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 1 country.

Martin BorlichHerz- und Gefäßzentrum, Segeberger Kliniken GmbH, Am Kurpark 1, Bad Segeberg, Schleswig-Holstein, 23795, Bad Segeberg, Germany. martin.borlich@segebergerkliniken.de.ORCID http://orcid.org/0000-0002-1608-4152
Uwe ZeymerMedizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Germany.
Harm WienbergenKlinikum Links der Weser Bremen, Bremen, Germany.
Hans-Peter HobbachKreisklinikum Siegen, Siegen, Germany.
Alessandro CuneoKrankenhaus und MVZ Maria-Hilf Stadtlohn, Stadtlohn, Germany.
Raffi BekeredjianRobert-Bosch-Klinikum, Stuttgart, Germany.
Oliver RitterKlinikum Brandenburg Havel, Brandenburg, Germany.
Birgit HailerKatholische Kliniken Essen-Nord-West gGmbH, Essen, Germany.
Klaus HerttingKrankenhaus Buchholz und Winsen GmbH, Buchholz, Germany.
Marcus HennersdorfSLK-Kliniken Heilbronn GmbH, Heilbronn, Germany.
Werner ScholtzHerz-und Diabeteszentrum, Bad Oeynhausen, Germany.
Peter LanzerGesundheitszentrum Bitterfeld Wolfen, Bitterfeld, Germany.
Harald MudraStädtisches Krankenhaus Neuperlach-München, Munich, Germany.
Markus SchweferElblandklinikum Riesa, Riesa, Germany.
Peter-Lothar SchwimmbeckKlinikum Leverkusen, Leverkusen, Germany.
Christoph LiebetrauKerckhoff-Klinik GmbH, Bad Nauheim, Germany.
Holger ThieleHerzzentrum Leipzig der Universität Leipzig, Leipzig, Germany.
Christoph ClaasInstitut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.
Thomas RiemerInstitut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.
Ralf ZahnMedizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Germany.
Leon IdenHerz- und Gefäßzentrum, Segeberger Kliniken GmbH, Am Kurpark 1, Bad Segeberg, Schleswig-Holstein, 23795, Bad Segeberg, Germany.
Gert RichardtHerz- und Gefäßzentrum, Segeberger Kliniken GmbH, Am Kurpark 1, Bad Segeberg, Schleswig-Holstein, 23795, Bad Segeberg, Germany.
Ralph ToelgHerz- und Gefäßzentrum, Segeberger Kliniken GmbH, Am Kurpark 1, Bad Segeberg, Schleswig-Holstein, 23795, Bad Segeberg, Germany.
Segeberger Kliniken · DEStiftung Institut für Herzinfarktforschung · DEChristian-Albrechts-Universität zu Kiel · DEDeutsches Herzzentrum der Charité · DEEmissions Reduzierungs Concepte (Germany) · DEGesundheitszentrum Bitterfeld · DEHeart and Diabetes Center North Rhine-Westphalia · DEKatholisches Klinikum Essen · DEKerckhoff Klinik · DEKlinikum Leverkusen · DEKlinikum Links der Weser · DEKlinikum Ludwigshafen · DEMünchen Klinik Neuperlach · DERobert Bosch Hospital · DESLK-Kliniken Heilbronn · DEUniversitätsklinikum Brandenburg an der Havel · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe preference for using transradial access (TRA) over transfemoral access (TFA) in patients requiring percutaneous coronary intervention (PCI) is based on evidence suggesting that TRA is associated with less bleeding and fewer vascular complications, shorter hospital stays, improved quality of life, and a potential beneficial effect on mortality. We have limited study data comparing the two access routes in a patient population with atrial fibrillation (AF) undergoing PCI, who have a particular increased risk of bleeding, while AF itself is associated with an increased risk of thromboembolism.

methodsUsing data from the RIVA-PCI registry, which includes patients with AF undergoing PCI, we analyzed a high-bleeding-risk (HBR) cohort. These patients were predominantly on oral anticoagulants (OAC) for AF, and the PCI was performed via radial or femoral access. Endpoints examined were in-hospital bleeding (BARC 2-5), cerebral events (TIA, hemorrhagic or ischemic stroke) and coronary events (stent thrombosis and myocardial infarction).

resultsOut of 1636 patients, 854 (52.2%) underwent TFA, while 782 (47.8%) underwent the procedure via TRA, including nine patients with brachial artery puncture. The mean age was 75.5 years. Groups were similar in terms of age, sex distribution, AF type, cardiovascular history, risk factors, and comorbidities, except for a higher incidence of previous bypass surgeries, heart failure, hyperlipidemia, and chronic kidney disease (CKD) with a glomerular filtration rate (GFR) < 60 ml/min in the TFA group. No clinically relevant differences in antithrombotic therapy and combinations were present at the time of PCI. However, upon discharge, transradial PCI patients had a higher rate of triple therapy, while dual therapy was preferred after transfemoral procedures. Radial access was more frequently chosen for non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris (UAP) cases (NSTEMI 26.6% vs. 17.0%, p < 0.0001; UAP 21.5% vs. 14.5%, p < 0.001), while femoral access was more common for elective PCI (60.3% vs. 44.1%, p < 0.0001). No differences were observed for ST-segment elevation myocardial infarction (STEMI). Both groups had similar rates of cerebral events (TFA 0.2% vs. TRA 0.3%, p = 0.93), but the TFA group had a higher incidence of bleeding (BARC 2-5) (4.2% vs. 1.5%, p < 0.01), mainly driven by BARC 3 bleeding (1.5% vs. 0.4%, p < 0.05). No significant differences were found for stent thrombosis and myocardial infarction (TFA 0.2% vs. TRA 0.3%, p = 0.93; TFA 0.4% vs. TRA 0.1%, p = 0.36).

conclusionsIn HBR patients with AF undergoing PCI for acute or chronic coronary syndrome, the use of TRA might be associated with a decrease in in-hospital bleeding, while not increasing the risk of embolic or ischemic events compared to femoral access. Further studies are required to confirm these preliminary findings.

Indexed as

Access siteDual therapyHigh-bleeding-riskIn-hospital bleedingPercutaneous coronary interventionRadial accessRIVA PCI

Identifiers

PMID38055177
PMCPMC10899132
OpenAlexW4389390116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.